Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study (2022)

Objective. To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods. Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response. Results. Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups. Conclusion. In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)579-589
Number of pages11
JournalJournal of Rheumatology
Volume40
Issue number5
DOIs
StatePublished - May 2013
  • Autoimmune diseases
  • B lymphocyte stimulator
  • Belimumab
  • Rheumatoid arthritis
  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • APA
  • Standard
  • Harvard
  • Vancouver
  • Author
  • BIBTEX
  • RIS

Stohl, W., Merrill, J. T., McKay, J. D., Lisse, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013). Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study. Journal of Rheumatology, 40(5), 579-589. https://doi.org/10.3899/jrheum.120886

(Video) Drug Discovery Panel

Efficacy and safety of belimumab in patients with rheumatoid arthritis : A phase II, randomized, double-blind, placebo-controlled, dose-ranging study. / Stohl, William; Merrill, Joan T.; McKay, James D. et al.

In: Journal of Rheumatology, Vol. 40, No. 5, 05.2013, p. 579-589.

Research output: Contribution to journalArticlepeer-review

Stohl, W, Merrill, JT, McKay, JD, Lisse, JR, Zhong, ZJ, Freimuth, WW & Genovese, MC 2013, 'Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study', Journal of Rheumatology, vol. 40, no. 5, pp. 579-589. https://doi.org/10.3899/jrheum.120886

Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study. Journal of Rheumatology. 2013 May;40(5):579-589. https://doi.org/10.3899/jrheum.120886

Stohl, William ; Merrill, Joan T. ; McKay, James D. et al. / Efficacy and safety of belimumab in patients with rheumatoid arthritis : A phase II, randomized, double-blind, placebo-controlled, dose-ranging study. In: Journal of Rheumatology. 2013 ; Vol. 40, No. 5. pp. 579-589.

@article{a43787b08f0f4af685781fd88ad9f8d8,

title = "Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study",

abstract = "Objective. To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods. Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response. Results. Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups. Conclusion. In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]. The Journal of Rheumatology",

keywords = "Autoimmune diseases, B lymphocyte stimulator, Belimumab, Rheumatoid arthritis",

author = "William Stohl and Merrill, {Joan T.} and McKay, {James D.} and Lisse, {Jeffrey R.} and Zhong, {Z. John} and Freimuth, {William W.} and Genovese, {Mark C.}",

year = "2013",

month = may,

doi = "10.3899/jrheum.120886",

language = "English (US)",

volume = "40",

pages = "579--589",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "5",

}

(Video) 4 Updates in Lupus Research

TY - JOUR

T1 - Efficacy and safety of belimumab in patients with rheumatoid arthritis

T2 - A phase II, randomized, double-blind, placebo-controlled, dose-ranging study

AU - Stohl, William

AU - Merrill, Joan T.

AU - McKay, James D.

AU - Lisse, Jeffrey R.

AU - Zhong, Z. John

AU - Freimuth, William W.

AU - Genovese, Mark C.

PY - 2013/5

Y1 - 2013/5

N2 - Objective. To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods. Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response. Results. Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups. Conclusion. In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]. The Journal of Rheumatology

AB - Objective. To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA). Methods. Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response. Results. Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups. Conclusion. In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]. The Journal of Rheumatology

KW - Autoimmune diseases

KW - B lymphocyte stimulator

(Video) Systemic Lupus Erythematosus: Pathology, Diagnosis, and Treatment -- ep. 32 of 32

KW - Belimumab

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84876889502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876889502&partnerID=8YFLogxK

U2 - 10.3899/jrheum.120886

DO - 10.3899/jrheum.120886

M3 - Article

C2 - 23547209

AN - SCOPUS:84876889502

VL - 40

SP - 579

EP - 589

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -

(Video) Therapy of Juvenile Dermatomyositis Past, Present & Emerging

(Video) Expert Recommendations from ACR on Psoriatic Arthritis, Ankylosing Spondylitis, Lupus, Vasculitis.

Videos

1. Session IX Who To Treat and When
(Iris Events Management)
2. Lupus Nephritis & ANCA-associated vasculitides: New Therapies
(Nephrology On-Demand)
3. Systemic Lupus Erythematosus: Pathology, Diagnosis, and Treatment -- ep. 12 of 32
(ClevelandClinicCME)
4. Dr Mostafa Sanad....1st FD scientific day......Lupus Erythrmatosus
(Free Dermatology)
5. Simposio Reumatologia Conferencia 3 - Urgencias en reumatología.
(Grupo Binomio)
6. Nefrite Lúpica - Gabriel Montezuma
(Preceptoria Nefro EPM)

You might also like

Latest Posts

Article information

Author: Francesca Jacobs Ret

Last Updated: 08/05/2022

Views: 6012

Rating: 4.8 / 5 (48 voted)

Reviews: 95% of readers found this page helpful

Author information

Name: Francesca Jacobs Ret

Birthday: 1996-12-09

Address: Apt. 141 1406 Mitch Summit, New Teganshire, UT 82655-0699

Phone: +2296092334654

Job: Technology Architect

Hobby: Snowboarding, Scouting, Foreign language learning, Dowsing, Baton twirling, Sculpting, Cabaret

Introduction: My name is Francesca Jacobs Ret, I am a innocent, super, beautiful, charming, lucky, gentle, clever person who loves writing and wants to share my knowledge and understanding with you.